Edmund Cannon Net Worth

The estimated Net Worth of Edmund Cannon is at least $279 mil dollars as of 31 January 2019. Mr. Cannon owns over 43,479 units of Cancer Genetics stock worth over $279,047 and over the last 11 years he sold CGIX stock worth over $0. In addition, he makes $0 as Independent Director at Cancer Genetics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Cannon CGIX stock SEC Form 4 insiders trading

Edmund has made over 1 trades of the Cancer Genetics stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 43,479 units of CGIX stock worth $10,000 on 31 January 2019.

The largest trade he's ever made was buying 43,479 units of Cancer Genetics stock on 31 January 2019 worth over $10,000. On average, Edmund trades about 5,435 units every 0 days since 2013. As of 31 January 2019 he still owns at least 61,873 units of Cancer Genetics stock.

You can see the complete history of Mr. Cannon stock trades at the bottom of the page.

Edmund Cannon biography

Edmund M. Cannon is the an Independent Director of Cancer Genetics, Inc. He is founder and President of the Clinical Research Center of Cape Cod, which specializes in finding institutional review board approved, consented specimens for the diagnostics and pharmaceutical industries, and in setting up studies to support FDA submissions for pharmaceutical and biotechnology companies. Previously, Mr. Cannon was a marketing and operations consultant for Franey Medical Labs. Mr. Cannon also formerly had the most national sales for Pharmacia Diagnostics Inc., and was a vice president and co-founder of Alletess, Inc. Mr. Canon has a degree from Boston State College and attended a Master's program at Providence College.

How old is Edmund Cannon?

Edmund Cannon is 72, he's been the Independent Director of Cancer Genetics since 2005. There are 2 older and 5 younger executives at Cancer Genetics. The oldest executive at Cancer Genetics Inc. is John Pappajohn, 90, who is the Non-Executive Chairman of the Board.

What's Edmund Cannon's mailing address?

Edmund's mailing address filed with the SEC is 201 NJ-17, Rutherford, NJ 07070, USA.

Insiders trading at Cancer Genetics

Over the last 11 years, insiders at Cancer Genetics have traded over $1,720,897 worth of Cancer Genetics stock and bought 3,891,559 units worth $4,573,241 . The most active insiders traders include John Pappajohn, Tommy G Thompson, eJohn A Roberts. On average, Cancer Genetics executives and independent directors trade stock every 35 days with the average trade being worth of $340,207. The most recent stock trade was executed by John A Roberts on 31 January 2019, trading 185,436 units of CGIX stock currently worth $42,650.

What does Cancer Genetics do?

Complete history of Mr. Cannon stock trades at Cancer Genetics

Cancer Genetics executives and stock owners

Cancer Genetics executives and other stock owners filed with the SEC include:

• Jane Houldsworth,
  Vice President - Research & Development
• Franklyn Prendergast,
  Independent Director
• Howard McLeod,
  Independent Director
• Edmund Cannon,
  Independent Director
• Thomas Widmann,
  Director
• Geoffrey Harris,
  Director
• John Roberts,
  President, Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer
• John Pappajohn,
  Non-Executive Chairman of the Board
• Panna Sharma,
  Chief Executive Officer
• Raju S.K. Chaganti,
  Director
• Michael J. Welsh,
  Director
• Edward J Sitar,
  Chief Financial Officer
• Igor Gitelman,
  Chief Accounting Officer
• Michael Brian Mc Cartney,
  Chief Commercial Officer
• Michael Glenn Miles,
  Chief Financial Officer
• Ralf Brandt,
  President, Discovery Services
• Rita Shaknovich,
  VP of Hematopathology Services
• Paul Rothman,
  Director
• Keith L Brownlie,
  Director
• Andrew L Pecora,
  Director
• Tommy G Thompson,
  Director
• Steven Hepburn,
  VP of Biopharma Marketing